1. Home
  2. FCO vs ADVM Comparison

FCO vs ADVM Comparison

Compare FCO & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FCO
  • ADVM
  • Stock Information
  • Founded
  • FCO 1991
  • ADVM 2006
  • Country
  • FCO United Kingdom
  • ADVM United States
  • Employees
  • FCO N/A
  • ADVM N/A
  • Industry
  • FCO Investment Managers
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FCO Finance
  • ADVM Health Care
  • Exchange
  • FCO Nasdaq
  • ADVM Nasdaq
  • Market Cap
  • FCO 85.6M
  • ADVM 94.6M
  • IPO Year
  • FCO N/A
  • ADVM 2014
  • Fundamental
  • Price
  • FCO $2.91
  • ADVM $4.93
  • Analyst Decision
  • FCO
  • ADVM Strong Buy
  • Analyst Count
  • FCO 0
  • ADVM 4
  • Target Price
  • FCO N/A
  • ADVM $19.75
  • AVG Volume (30 Days)
  • FCO 100.1K
  • ADVM 746.8K
  • Earning Date
  • FCO 01-01-0001
  • ADVM 11-03-2025
  • Dividend Yield
  • FCO 14.96%
  • ADVM N/A
  • EPS Growth
  • FCO N/A
  • ADVM N/A
  • EPS
  • FCO 0.43
  • ADVM N/A
  • Revenue
  • FCO N/A
  • ADVM $1,000,000.00
  • Revenue This Year
  • FCO N/A
  • ADVM $1,449.40
  • Revenue Next Year
  • FCO N/A
  • ADVM N/A
  • P/E Ratio
  • FCO $12.30
  • ADVM N/A
  • Revenue Growth
  • FCO N/A
  • ADVM N/A
  • 52 Week Low
  • FCO $4.73
  • ADVM $1.78
  • 52 Week High
  • FCO $6.63
  • ADVM $8.56
  • Technical
  • Relative Strength Index (RSI)
  • FCO 10.15
  • ADVM 66.10
  • Support Level
  • FCO $2.88
  • ADVM $4.01
  • Resistance Level
  • FCO $3.13
  • ADVM $5.58
  • Average True Range (ATR)
  • FCO 0.09
  • ADVM 0.63
  • MACD
  • FCO 0.06
  • ADVM 0.10
  • Stochastic Oscillator
  • FCO 7.19
  • ADVM 71.60

About FCO abrdn Global Income Fund Inc.

abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Share on Social Networks: